CNS PHARMACEUTICALS INC (CNSP)
US18978H3003 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 54.53% | N/A 37.36% | N/A 28.78% | ||||||||
| EBITDA YoY % growth | N/A | N/A | -3.83M | -9.44M -146.48% | -14.48M -53.39% | -15.26M -5.39% | -18.861M -23.60% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -220K | -880K -300.00% | -3.83M -335.23% | -9.45M -146.74% | -14.49M -53.33% | -15.27M -5.38% | -18.865M -23.54% | N/A 31.08% | N/A -24.91% | N/A -30.42% | N/A 150.03% | N/A 361.68% | N/A 92.34% | N/A 43.39% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -855.00 -408.02% | -810.00 5.26% | N/A 98.72% | N/A -17.65% | N/A 92.92% | N/A 54.12% | N/A 7.69% | N/A | N/A | N/A | N/A |
All data in USD
| Q4 / 24 | |
|---|---|
| EPS Q2Q % growth | -0.12 |
| Revenue Q2Q % growth | |
| EBITDA Q2Q % growth | N/A |
| EBIT Q2Q % growth | -3.714M 30.96% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.25 76.85% | -0.10 | -0.15 | -145.10% |
| Q3 2023 Q2Q % growth | -1.08 99.20% | % | ||
| Q1 2023 Q2Q % growth | -2.59 97.53% | % | ||
| Q4 2022 Q2Q % growth | 98.37% | -2.45 | % | |
| Q3 2022 Q2Q % growth | -135.00 35.71% | -122.40 | -12.60 | -10.29% |
| Q2 2022 Q2Q % growth | -135.00 40.00% | -122.40 | -12.60 | -10.29% |
| Q1 2022 Q2Q % growth | -105.00 53.33% | -168.30 | 63.30 | 37.61% |
| Q4 2021 Q2Q % growth | -150.00 44.44% | -244.80 | 94.80 | 38.73% |
| Q3 2021 Q2Q % growth | -210.00 -16.67% | -248.63 | 38.63 | 15.54% |
| Q2 2021 Q2Q % growth | -225.00 | -198.90 | -26.10 | -13.12% |
| Q1 2021 Q2Q % growth | -225.00 -25.00% | -183.60 | -41.40 | -22.55% |
| Q4 2020 Q2Q % growth | -270.00 -5.88% | -179.78 | -90.23 | -50.19% |
| Q3 2020 Q2Q % growth | -180.00 -140.00% | -191.25 | 11.25 | 5.88% |
| Q2 2020 Q2Q % growth | -225.00 | -122.40 | -102.60 | -83.82% |
| Q1 2020 Q2Q % growth | -180.00 | -153.00 | -27.00 | -17.65% |
| Q4 2019 Q2Q % growth | -255.00 | -45.90 | -209.10 | -455.56% |
| Q3 2019 Q2Q % growth | -75.00 | -45.90 | -29.10 | -63.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | N/A | 0% | 94.85% |
| Revenue | N/A | N/A | N/A | N/A |